RxDoctor Payments DataLook up a doctor →

Nadia Cameron, MD

Family Medicine · Atlanta, GANPI 1033134556

Payments from drug & device makers

$2,064,974in general payments, 2019–2025

Across 154 payments — averaging $13,409 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • Regeneron$787K
  • Merck$103K
  • Sumitomo Pharma America, Inc.$31K
  • Chiesi USA, Inc.$26K
  • Shionogi Inc$1K
  • plus $672 from 7 others
$180,326in research payments, 2019–2025

Across 18 payments — averaging $10,018 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$179K
  • Regeneron$1K

What the payments were for

  • Travel & lodging$2,05861%
  • Food & beverage$1,20336%
  • Education$1003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,064,974 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$7,088
Medicare patients
19
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$26,473
RybelsusSemaglutide17$20,073
JanuviaSitagliptin Phosphate13$17,896
LinzessLinaclotide14$13,522
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$2,178
Megestrol Acetate11$1,645
Omeprazole57$816
Losartan Potassium96$789
Atorvastatin Calcium142$785
Gabapentin75$712
Amlodipine Besylate172$615
Albuterol Sulfate HfaAlbuterol Sulfate27$591
Venlafaxine Hcl ErVenlafaxine Hcl13$548
Levothyroxine Sodium60$458
Buspirone Hcl12$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$102$46,54636 claims
MerckJanuvia$103,013$17,89613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →